Peptides for libido: what is studied, and what is not
The compounds sold for sexual desire, what has been tested in people, and where the evidence stops. Low desire and erectile problems are different, and each has its own treatment.
Products in this guide
The short answer for each goal.
| If your goal is | The approach | What is in it | Price |
|---|---|---|---|
| Low desire, premenopausal women, in research | PT-141, tested as bremelanotide | PT-141 | Prescribed after a clinician review |
| Reproductive hormones, in research | Kisspeptin-10 | Kisspeptin-10 | Prescribed after a clinician review |
| Testosterone signaling in men, in research | hCG | hCG | Prescribed after a clinician review |
Each product has its own page with its composition and concentration. Erectile problems are a different issue, with their own treatments listed in the table below.
What drives desire, and what has been tested.
Desire depends on the brain, hormones, mood, sleep and the relationship. The compounds in this guide were chosen for a link to one of those parts. A link to a part of the system is not evidence that a product helps desire in people.
Desire circuits
Bremelanotide, the name under which PT-141 was tested, was studied in phase 3 trials for desire in premenopausal women [1].
The hormone axis
Kisspeptin signals the pituitary to release LH and FSH, which drive testosterone in men. Short and multi-day infusions raised these hormones in healthy men [2][3].
Desire and erection
Low desire and erectile problems are different, with different causes and treatments. Your clinician sorts out which one you have before anything else.
Mixed blends
The blend with MOTS-c, BPC-157, GHK-Cu and kisspeptin-10 has no trial in people cited in this guide.
These four points are a way to read the guide. They are not a claim that any product treats them.
The products, one by one.
Each card shows the composition and concentration as the pharmacy loads them. Your clinician sets any dose for your case. We do not publish dose figures here, because most of these compounds have no established human dose.
Single compound
hCG
- Composition and concentration
- 5000 IU
- How it is given
- Injection under the skin
From $249/mo
View productKisspeptin-10
- Composition and concentration
- 2 mg/mL, 5 mL vial
- How it is given
- Injection under the skin
Prescribed after a clinician review
Start intakePT-141
- Composition and concentration
- 2 mg/mL, 5 mL vial
- How it is given
- Injection under the skin
From $159/mo
View product
Blends
MOTS-c / BPC-157 / GHK-Cu / Kisspeptin-10
- Composition and concentration
- 2 mg / 2 mg / 10 mg / 0.4 mg/mL, 5 mL vial
- How it is given
- Injection under the skin
Prescribed after a clinician review
Start intake
What the evidence shows and what it does not.
The best human data are for bremelanotide, in two phase 3 trials of women. For kisspeptin, the human studies are short and small, and they measure hormones, not desire.
What exists
- In two phase 3 trials in premenopausal women with hypoactive sexual desire disorder, bremelanotide improved sexual desire and related distress compared with placebo [1].
- In those trials, bremelanotide caused more nausea, flushing and headache than placebo. Most adverse events were mild or moderate [1].
- A short kisspeptin-54 infusion raised LH, FSH and testosterone in healthy men [2].
- A 12-day subcutaneous kisspeptin-10 protocol kept gonadotropin and testosterone levels raised in healthy men [3].
What is missing
- The phase 3 trials enrolled premenopausal women with hypoactive sexual desire disorder. They do not show the same for other people.
- The kisspeptin studies were small, in healthy men, and measured hormones. They did not report desire or satisfaction [2][3].
- No trial of kisspeptin for desire in women is cited in this guide.
- The blends have no trial in people cited in this guide.
- The compounded vials sold here are not the product tested in those trials.
Numbers in brackets point to the reference list at the end of the guide.
Where these stand with the FDA.
Compounded medications are not FDA-approved for safety, efficacy or quality, and a licensed pharmacy in the United States prepares them with a prescription from a physician. The FDA has approved a bremelanotide product for hypoactive sexual desire disorder in premenopausal women. That approved product is not the compounded vial. hCG has approved labels for specific medical uses, not for sexual desire. This guide does not describe any FDA approval for kisspeptin or the blends. Status can change, so your clinician and pharmacy confirm it before any prescription.
Who should not use them, and when another option fits better.
These are the cases where a clinician should not start, or should wait. The list is not complete: your clinician reviews your history before any prescription.
| Situation | Why |
|---|---|
| Pregnancy, trying to conceive or breastfeeding | These products act on reproductive hormones. Your clinician reviews your plans first. |
| Erection problems or trouble with blood flow | This is a different problem from low desire, and it often has other treatments. Sildenafil and tadalafil are in our catalog, with prices on their pages. Some medicines, such as nitrates, must not be combined with them, so your clinician checks your full list. |
| Blood pressure problems, heart disease or a past stroke | PT-141 can raise blood pressure briefly. Your clinician checks blood pressure and your heart history first. |
| Active cancer, or a hormone-sensitive cancer | There are no safety data for these compounds in people with active cancer. Your clinician decides first. |
| Low testosterone with symptoms | Testosterone is measured with a blood test first. Hormone therapy is a separate decision with its own monitoring. |
| Low desire linked to mood, sleep, alcohol, medicines or the relationship | These are often the first things a clinician reviews, before any peptide. |
What to expect, and when.
There is no validated timeline in people for desire with these compounds. Agree with your clinician what to track and how often to review it.
- What to track: your own notes on desire and distress, agreed with your clinician at the start.
- When to review: at the follow-up visits your clinician schedules.
- What not to expect: evidence that these products work for you, or that they are safe for every person.
Tests and monitoring your clinician decides.
Your clinician decides which tests to order before you start and during treatment, based on your history. They tell you which ones and when.
- Before: your full history, blood pressure, and the hormone tests your clinician considers necessary.
- During: review at the visits, blood pressure checks, and the tests your clinician orders.
References
Only studies indexed in PubMed, with the title and year as they appear there.
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol, 2019
- Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab, 2005
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol, 2026
Common questions
Which of these has the most evidence in people?
PT-141, tested as bremelanotide, has phase 3 trials for desire in premenopausal women. The approved product is not the compounded vial.
Will it work for me?
No study cited here shows how any of these works for an individual. Your clinician reviews your history and decides.
What are the side effects?
In the phase 3 trials, bremelanotide caused more nausea, flushing and headache than placebo. Your clinician reviews your history before any prescription.
Is it safe with other medicines?
Your clinician checks your full list of medicines before any prescription, including any treatment for erection problems.
How much do they cost?
Products with a public price show it on their page. The others are prescribed after a clinician review, so start with the intake to learn about your case.
Where do I start?
With the intake. A clinician reviews your history and decides whether any of these fits, or whether another option is better.
Start with a clinician review.
Complete the intake. A physician in our practice reviews your history before anything is prescribed.
